On one hand, CDADC1 deficiency enhances the sensitivity of human cancer cells to gemcitabine and decitabine, increasing the antitumor efficacy of gemcitabine in mouse models of pancreatic cancer at a dose equivalent to ~380 mg/m2. The gene discussed is CDADC1; the disease is familial pancreatic carcinoma.